Back to Results
First PageMeta Content
Hypohidrotic ectodermal dysplasia / Genodermatoses / EDA / Ectodermal dysplasia


  Edimer  Initiates  Phase  2  Trial  of  EDI200  in  XLHED-­‐Affected  Male  Newborns       -­‐-­‐  First  neonate  subject  with  X-­‐linked  hypohid
Add to Reading List

Document Date: 2013-10-08 08:11:28

Open Document

File Size: 131,27 KB

Share Result on Facebook

City

Cambridge / XLHED / /

Company

VI Partners / AEs / Sanofi / Edimer Pharmaceuticals / Rock Ventures / Genzyme / Siemens / /

Continent

Europe / /

Country

United States / /

Event

FDA Phase / Funding / /

/

IndustryTerm

biotechnology / therapy for the rare genetic disorder / /

MedicalCondition

Touraine Syndrome / lung inflammation / developmental disorder / rare genetic disorder X / significant pneumonias / eczema / respiratory infections / rare disorder / disorder / hypohidrotic ectodermal dysplasia / chronic sinusitis / specific developmental disorder / rare orphan disease / asthma / /

MedicalTreatment

innovative therapy / /

Organization

U.S. Food and Drug Administration / /

Person

Vora / Kirby / /

/

Position

President of the Board of Directors / President and CEO / /

Product

EDI200 / Phase / Europe / /

ProvinceOrState

Massachusetts / /

Technology

pharmacokinetics / biotechnology / pharmacodynamics / /

URL

www.edimerpharma.com / www.xlhednetwork.com / /

SocialTag